Item 7.01. Regulation FD Disclosure.
On May 14, 2020, Krystal Biotech, Inc. (the "Company") issued a press release
announcing positive results from its Phase 1/2 interim results for a
first-in-human Phase 1/2 placebo controlled clinical trial evaluating topical
administration of KB105 in patients with autosomal recessive congenital
ichthyosis (ARCI). Amy Paller, M.D., Professor and Chair of Dermatology at
Northwestern University, will present detailed results from the clinical trial
at the Society for Investigative Dermatology (SID) annual meeting on May 14,
2020. A copy of the press release is furnished as Exhibit 99.1 to this Current
Report on Form 8-K.
This information in this Item 7.01 of this Current Report on Form 8-K shall not
be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of
1934, as amended, or otherwise subject to the liabilities of that Section, or
incorporated by reference in any filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit
No. Description
99.1 Press Release, dated May14, 2020.
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses